Literature DB >> 31787614

DNA damage on the DOCK in FLT3-ITD-driven acute myeloid leukemia.

Ruchi Pandey1, Reuben Kapur2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31787614      PMCID: PMC6959170          DOI: 10.3324/haematol.2019.231340

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.

Authors:  Olga A Guryanova; Kaitlyn Shank; Barbara Spitzer; Luisa Luciani; Richard P Koche; Francine E Garrett-Bakelman; Chezi Ganzel; Benjamin H Durham; Abhinita Mohanty; Gregor Hoermann; Sharon A Rivera; Alan G Chramiec; Elodie Pronier; Lennart Bastian; Matthew D Keller; Daniel Tovbin; Evangelia Loizou; Abby R Weinstein; Adriana Rodriguez Gonzalez; Yen K Lieu; Jacob M Rowe; Friederike Pastore; Anna Sophia McKenney; Andrei V Krivtsov; Wolfgang R Sperr; Justin R Cross; Christopher E Mason; Martin S Tallman; Maria E Arcila; Omar Abdel-Wahab; Scott A Armstrong; Stefan Kubicek; Philipp B Staber; Mithat Gönen; Elisabeth M Paietta; Ari M Melnick; Stephen D Nimer; Siddhartha Mukherjee; Ross L Levine
Journal:  Nat Med       Date:  2016-11-14       Impact factor: 53.440

2.  Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.

Authors:  Silvia Maifrede; Margaret Nieborowska-Skorska; Katherine Sullivan-Reed; Yashodhara Dasgupta; Paulina Podszywalow-Bartnicka; Bac Viet Le; Martyna Solecka; Zhaorui Lian; Elizaveta A Belyaeva; Alina Nersesyan; Marcin M Machnicki; Monika Toma; Nicolas Chatain; Malgorzata Rydzanicz; Huaqing Zhao; Jaroslav Jelinek; Katarzyna Piwocka; Tomasz Sliwinski; Tomasz Stoklosa; Rafal Ploski; Thomas Fischer; Stephen M Sykes; Steffen Koschmieder; Lars Bullinger; Peter Valent; Mariusz A Wasik; Jian Huang; Tomasz Skorski
Journal:  Blood       Date:  2018-05-21       Impact factor: 22.113

3.  Blockade of inflammatory responses by a small-molecule inhibitor of the Rac activator DOCK2.

Authors:  Akihiko Nishikimi; Takehito Uruno; Xuefeng Duan; Qinhong Cao; Yuji Okamura; Takashi Saitoh; Nae Saito; Shunsuke Sakaoka; Yao Du; Atsushi Suenaga; Mutsuko Kukimoto-Niino; Kei Miyano; Kazuhito Gotoh; Takayoshi Okabe; Fumiyuki Sanematsu; Yoshihiko Tanaka; Hideki Sumimoto; Teruki Honma; Shigeyuki Yokoyama; Tetsuo Nagano; Daisuke Kohda; Motomu Kanai; Yoshinori Fukui
Journal:  Chem Biol       Date:  2012-04-20

4.  Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.

Authors:  Richard M Stone; Sumithra J Mandrekar; Ben L Sanford; Kristina Laumann; Susan Geyer; Clara D Bloomfield; Christian Thiede; Thomas W Prior; Konstanze Döhner; Guido Marcucci; Francesco Lo-Coco; Rebecca B Klisovic; Andrew Wei; Jorge Sierra; Miguel A Sanz; Joseph M Brandwein; Theo de Witte; Dietger Niederwieser; Frederick R Appelbaum; Bruno C Medeiros; Martin S Tallman; Jürgen Krauter; Richard F Schlenk; Arnold Ganser; Hubert Serve; Gerhard Ehninger; Sergio Amadori; Richard A Larson; Hartmut Döhner
Journal:  N Engl J Med       Date:  2017-06-23       Impact factor: 91.245

Review 5.  PARP inhibitors: Synthetic lethality in the clinic.

Authors:  Christopher J Lord; Alan Ashworth
Journal:  Science       Date:  2017-03-16       Impact factor: 47.728

6.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).

Authors:  John C Byrd; Krzysztof Mrózek; Richard K Dodge; Andrew J Carroll; Colin G Edwards; Diane C Arthur; Mark J Pettenati; Shivanand R Patil; Kathleen W Rao; Michael S Watson; Prasad R K Koduru; Joseph O Moore; Richard M Stone; Robert J Mayer; Eric J Feldman; Frederick R Davey; Charles A Schiffer; Richard A Larson; Clara D Bloomfield
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

Review 7.  Rac1 in human diseases: The therapeutic potential of targeting Rac1 signaling regulatory mechanisms.

Authors:  Hadir Marei; Angeliki Malliri
Journal:  Small GTPases       Date:  2016-07-21

8.  Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells.

Authors:  Feng Pan; Thomas S Wingo; Zhigang Zhao; Rui Gao; Hideki Makishima; Guangbo Qu; Li Lin; Miao Yu; Janice R Ortega; Jiapeng Wang; Aziz Nazha; Li Chen; Bing Yao; Can Liu; Shi Chen; Ophelia Weeks; Hongyu Ni; Brittany Lynn Phillips; Suming Huang; Jianlong Wang; Chuan He; Guo-Min Li; Tomas Radivoyevitch; Iannis Aifantis; Jaroslaw P Maciejewski; Feng-Chun Yang; Peng Jin; Mingjiang Xu
Journal:  Nat Commun       Date:  2017-04-25       Impact factor: 14.919

9.  DOCK2 interacts with FLT3 and modulates the survival of FLT3-expressing leukemia cells.

Authors:  M Wu; M Hamaker; L Li; D Small; A S Duffield
Journal:  Leukemia       Date:  2016-10-17       Impact factor: 11.528

10.  FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.

Authors:  Min Wu; Li Li; Max Hamaker; Donald Small; Amy S Duffield
Journal:  Haematologica       Date:  2019-04-11       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.